It has been demonstrated that cancer cell senescence induced by CDK4/6 inhibition can promote the development of more aggressive drug-resistant cancer stem cells [50–52] leading to attenuated response to anti-tumor agents and cancer recurrence. This evidence concerns the gene CDK4 and neoplasm.